Genetic eye disease

Dr Jasleen Jolly has expertise of working with genetic eye diseases, particularly inherited retinal diseases.

She has previously been involved in a number of therapeutic trials for new therapies, including first-in-humans trials and gene therapy. From this work, Dr Jolly has identified the importance of a number of issues at stake in increasing the success of these trials:

• Use of appropriate outcome measures
• Genotype/phenotype correlations
• Better understanding of disease mechanisms
• Multi-disciplinary approaches to trial protocol development

VERI is working with multiple partners both within ARU and multinationally to:

• Explore novel therapeutic interventions for the treatment of genetic eye diseases
• Develop novel outcome measures
• Study phenotype patterns in order to better inform both clinical care and research studies

A range of tools is utilised to probe visual function at multiple levels and to understand structure-function correlations, keeping in mind regulatory requirements for outcome measure development.

Equipment is available for both imaging and functional analysis, including access to clinical electrophysiology.

We are currently recruiting for an active project designing mobility outcome measures to be used in future clinical trials (in conjunction with the Faculty of Science and Engineering).

You can view our latest publications on the VERI publications page.